<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To describe the demographic and clinical features, complications, treatment, and visual results in patients with <z:hpo ids='HP_0011463'>childhood-onset</z:hpo> <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Observational case series </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A retrospective study was made of 36 consecutive patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease seen at the <z:hpo ids='HP_0000554'>Uveitis</z:hpo> Service, Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, between January 1975 and January 2002 </plain></SENT>
<SENT sid="3" pm="."><plain>Inclusion criteria were fulfillment of the classification criteria of the International Study Group for <z:chebi fb="6" ids="22696">Beh</z:chebi>çet Disease and <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0000554'>uveitis</z:hpo> at 16 years of age or younger </plain></SENT>
<SENT sid="4" pm="."><plain>The medical records of 36 patients with <z:hpo ids='HP_0011463'>childhood-onset</z:hpo> <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> were reviewed </plain></SENT>
<SENT sid="5" pm="."><plain>The main outcome measures were sex, age at <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0000554'>uveitis</z:hpo>, the initial symptom of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease, clinical ocular features, ocular complications, systemic treatment, complications of treatment, and final visual acuity </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Twenty-five patients were male, 11 were female </plain></SENT>
<SENT sid="7" pm="."><plain>Mean age at <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0000554'>uveitis</z:hpo> was 13.6 years </plain></SENT>
<SENT sid="8" pm="."><plain>The initial symptom was <z:hpo ids='HP_0000155'>oral ulcer</z:hpo> in 63.8% of the patients </plain></SENT>
<SENT sid="9" pm="."><plain>The majority of patients (83.3%) had bilateral involvement </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0012121'>Panuveitis</z:hpo> was the most common form (86.2%) </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="46" ids="15035">Retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and <z:e sem="disease" ids="C0035333" disease_type="Disease or Syndrome" abbrv="">retinitis</z:e> were the most common ocular findings seen in 83.3% and 68.2% of the involved eyes, respectively </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0000518'>Cataract</z:hpo>, <z:e sem="disease" ids="C0730362" disease_type="Disease or Syndrome" abbrv="">maculopathy</z:e>, and <z:hpo ids='HP_0000648'>optic atrophy</z:hpo> were the most common complications seen in 46.9%, 45.4%, and 39.4% of the involved eyes, respectively </plain></SENT>
<SENT sid="13" pm="."><plain>Immunosuppressive therapy was administered to 75% of the patients </plain></SENT>
<SENT sid="14" pm="."><plain>Response to treatment was variable </plain></SENT>
<SENT sid="15" pm="."><plain>The most common complications of systemic treatment were associated with <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy </plain></SENT>
<SENT sid="16" pm="."><plain>Final visual acuity was worse than 0.1 in 22.7% of the involved eyes </plain></SENT>
<SENT sid="17" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0011463'>Childhood-onset</z:hpo> <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> was more common among males </plain></SENT>
<SENT sid="18" pm="."><plain>Bilateral <z:hpo ids='HP_0012121'>panuveitis</z:hpo> with <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and <z:e sem="disease" ids="C0035333" disease_type="Disease or Syndrome" abbrv="">retinitis</z:e> was the most common form of ocular involvement, similar to the adult patient </plain></SENT>
<SENT sid="19" pm="."><plain>The treatment is challenging, as the use oral <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> is associated with significant complications and the response to conventional immunosuppressive therapy is variable </plain></SENT>
</text></document>